Skip to main content
U

UnicoCell Biomed Co., Ltd. — Investor Relations & Filings

Ticker · 6794 TW Professional, scientific and technical activities
Filings indexed 20 across all filing types
Latest filing 2026-04-30 Regulatory Filings
Country TW Taiwan
Listing TW 6794

About UnicoCell Biomed Co., Ltd.

https://www.unicocell.com

UnicoCell Biomed Co., Ltd. specializes in regenerative medicine, focusing on the research, development, and clinical application of stem cell technologies. The company’s operations are centered on three primary axes: the development of novel stem cell therapeutics, the production of stem cell-derived exosomes, and the provision of cell manufacturing and Contract Development and Manufacturing Organization (CDMO) services. Its lead candidate, ELIXCYTE, is an adipose-derived stem cell therapy undergoing Phase 3 clinical trials for indications such as knee osteoarthritis and chronic kidney disease. Additionally, the company maintains an allogeneic stem cell bank and provides autologous adipose-derived stem cell therapy services. Utilizing patented manufacturing processes and proprietary technology, UnicoCell offers integrated solutions from research to large-scale production to address unmet medical needs in the regenerative therapy sector.

Recent filings

Filing Released Lang Actions
公告本公司115年第一季財務報告董事會召開日期
Regulatory Filings
2026-04-30 Chinese
114年年報及股東會資料 — 2025_6794_20260520FE4.pdf
Regulatory Filings
2026-04-30 English
114年年報及股東會資料 — 2025_6794_20260520F04.pdf
Regulatory Filings
2026-04-30 Chinese
114年第4季財務報告書 — 202504_6794_AIB.pdf
Regulatory Filings
2026-04-29 Chinese
114年第4季財務報告書 — 202504_6794_AI2.pdf
Regulatory Filings
2026-04-29 Chinese
114年第4季財務報告書 — 202503_6794_AI2.pdf
Regulatory Filings
2026-04-29 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.